Article

IL-6 modulates CD5 expression in B cells from patients with lupus by regulating DNA methylation.

Research Unit EA2216 Immunology and Pathology, IFR148 ScInBioS, Université de Brest, Brest, France.
The Journal of Immunology (Impact Factor: 5.36). 06/2009; 182(9):5623-32. DOI: 10.4049/jimmunol.0802412
Source: PubMed

ABSTRACT B lymphocytes from patients with systemic lupus erythematosus (SLE) are characterized by reduced expression levels of membrane CD5. Recent studies from our laboratory have revealed that the level of membrane CD5 is determined by the relative level of two alternative CD5 isoforms; CD5-E1A, which is expressed on the membrane, and CD5-E1B, which is retained in the cytoplasm. Using bisulfite sequencing and methylation-sensitive endonuclease assays we show that the promoter for the alternative CD5-E1B isoform is demethylated in B cells from patients with SLE but not in healthy controls. We go on to show that differential methylation is more pronounced following BCR engagement. As a result of this demethylation, CD5-E1B mRNA is transcribed at the expense of CD5-E1A mRNA transcription. We provide further evidence that production of high IL-6 levels by SLE B cells abrogates the ability of SLE B cells to induce DNA methyl transferase (DNMT1) and then to methylate DNA, an effect that is reversed in the presence of a blocking Ab to the IL-6 receptor. The pattern of demethylation of CpG islands in the CD5-E1B promoter in SLE B cells is similar to those in B cells from healthy controls stimulated in the presence of IL-6, or treated with the methylation inhibitor PD98059. The study reveals that engagement of the BCR with constitutive IL-6 down-regulates the level of membrane CD5, which negatively regulates BCR signaling, in SLE B cells. This altered signaling could, in turn, promote the activation and expansion of autoreactive B cells in SLE patients.

0 Followers
 · 
215 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: B-cell development is a multistep process sustained by a highly coordinated transcriptional network under the control of a limited set of transcription factors. Epigenetic mechanisms, including DNA methylation, histone posttranslational modifications and microRNAs act in concert with transcription factors to promote lineage commitment, define and sustain cell identity and establish heritable cell-type- and stage-specific gene expression profiles. Epigenetic modifiers have recently emerged as key regulators of B-cell development and activation. Central to B-cell-mediated immunity are germinal centers, transient structures formed in secondary lymphoid organs where antigen-specific B cells undergo intense proliferation, immunoglobulin somatic hypermutation and isotype switching, to generate ultimately long-lived memory B cells and terminally differentiated plasma cells expressing high-affinity antibodies. Deregulation of one or more epigenetic axes represents a common feature of several B-cell disorders arising from germinal center B cells, including autoimmunity and lymphoma. Moreover, the hijacking of epigenetic determinants is central to the ability of the B-lymphotropic Epstein–Barr virus (EBV) to establish, via the germinal center reaction, life-long latency and occasionally contribute to malignant B-cell transformation. In the light of recent findings, this review will discuss the relevance of epigenetic deregulation in the pathogenesis of B-cell diseases. Understanding how specific epigenetic alterations contribute to the development of lymphomas, autoimmunity and EBV-associated disorders is instrumental to develop novel therapeutic interventions for the cure of these often fatal pathologies.
    Immunology and Cell Biology 01/2015; 93(3):1-8. DOI:10.1038/icb.2014.116 · 4.21 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Previous studies have reported that the DNA of T cells from systemic lupus erythematosus (SLE) patients contains global hypomethylation that may contribute to the development of SLE. Human endogenous retroviruses (HERVs) are encoded within the genomes of all higher eukaryotes and are of special interest where autoimmune disorders are concerned. Until recently, minimal effort has been made to identify specific HERVs associated with SLE and to explore their precise mechanism of expression. To examine the expression of HERVs associated with SLE and elucidate the effect of ultraviolet B (UVB) exposure on SLE-associated HERV expression in CD4+ T cells from patients with SLE. Fifteen patients with SLE and 10 healthy controls were enrolled in the study. The mRNA expression of selected HERVs and the methylation status of the long terminal repeats (LTRs) in SLE-related HERVs in CD4+ T cells were investigated. Furthermore, CD4+ T cells treated with 5-aza-deoxycytidine (5-aza C) and UVB were analyzed. Reverse-transcription PCR (RT-PCR), quantitative real-time PCR (qRT-PCR) and bisulfite sequencing analysis were employed. HERV-E mRNA expression was higher in lupus CD4+ T cells than in cells from healthy controls, whereas the mRNA expression levels of HERV-K, HERV-K10 and HERV-W were comparable in SLE patients and healthy controls. Additionally, the HERV-E mRNA expression level was positively correlated with SLE disease activity. Furthermore, the HERV-E LTR methylation level was decreased and was negatively correlated to the HERV-E mRNA expression level in lupus CD4+ T cells. Finally, lupus CD4+ T cells showed markedly decreased HERV-E LTR2C methylation levels and increased HERV-E mRNA expression after treatment with 5-aza C or UVB. HERV-E is involved in the development of SLE. HERV-E transcription may be activated via inhibition of LTR methylation in lupus CD4+ T cells. Copyright © 2015 Japanese Society for Investigative Dermatology. Published by Elsevier Ireland Ltd. All rights reserved.
    Journal of Dermatological Science 01/2015; 77(2). DOI:10.1016/j.jdermsci.2014.12.004 · 3.34 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Autoimmune diseases occur more often in females, suggesting a key role for the X chromosome. X chromosome inactivation, a major epigenetic feature in female cells that provides dosage compensation of X-linked genes to avoid overexpression, presents special vulnerabilities that can contribute to the disease process. Disruption of X inactivation can result in loss of dosage compensation with expression from previously sequestered genes, imbalance of gene products and altered endogenous material out of normal epigenetic context. In addition, the human X has significant differences compared to other species and these differences can contribute to the frequency and intensity of the autoimmune disease in humans as well as the types of autoantigens encountered. Here a link is demonstrated between autoimmune diseases, such as systemic lupus erythematosus, and the X chromosome by discussing cases in which typically non-autoimmune disorders complicated with X chromosome abnormalities also present lupus like symptoms. The discussion is then extended to the reported spatial and temporal associations of the inactive X chromosome with the nucleolus. When frequent episodes of cellular stress occur, the inactive X chromosome may be disrupted and inadvertently become involved in the nucleolar stress response. Development of autoantigens, many of which are at least transiently components of the nucleolus, are then described. Polyamines, which aid in nucleoprotein complex assembly in the nucleolus, increase further during cell stress, and appear to have an important role in the autoimmune disease process. Autoantigenic endogenous material can potentially be stabilized by polyamines. This presents a new paradigm for autoimmune diseases: that many are antigen-driven and the autoantigens originate from altered endogenous material due to episodes of cellular stress that disrupt epigenetic control. This suggests that epigenetics and the X chromosome are important aspects of autoimmune diseases.
    Frontiers in Genetics 01/2015; 6. DOI:10.3389/fgene.2015.00022

Full-text (2 Sources)

Download
56 Downloads
Available from
May 21, 2014